Toronto Dominion Bank lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% during the second quarter, Holdings Channel reports. The fund owned 283,143 shares of the medical research company’s stock after selling 1,544 shares during the period. Toronto Dominion Bank’s holdings in Thermo Fisher Scientific were worth $83,132,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of TMO. Massey Quick Simon & CO. LLC acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $30,000. Redhawk Wealth Advisors Inc. bought a new position in Thermo Fisher Scientific in the second quarter valued at approximately $31,000. Capital Advisors Ltd. LLC boosted its stake in Thermo Fisher Scientific by 250.0% in the second quarter. Capital Advisors Ltd. LLC now owns 140 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 100 shares during the last quarter. MRA Associates USA LLC bought a new position in Thermo Fisher Scientific in the second quarter valued at approximately $43,000. Finally, Focused Wealth Management Inc acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth $44,000. Hedge funds and other institutional investors own 88.19% of the company’s stock.

A number of research analysts have recently weighed in on TMO shares. Wolfe Research assumed coverage on Thermo Fisher Scientific in a research note on Thursday, May 30th. They issued an “outperform” rating on the stock. UBS Group lifted their price objective on Thermo Fisher Scientific from $305.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, May 23rd. Needham & Company LLC upped their price objective on Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 target price on the stock in a research note on Wednesday, June 12th. Finally, Credit Suisse Group restated a “buy” rating and set a $310.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Thermo Fisher Scientific presently has an average rating of “Buy” and an average price target of $303.17.

In related news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $284.83, for a total value of $14,241,500.00. Following the sale, the chief executive officer now directly owns 342,193 shares of the company’s stock, valued at approximately $97,466,832.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jim P. Manzi sold 1,833 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $272.93, for a total transaction of $500,280.69. Following the completion of the transaction, the director now directly owns 28,592 shares of the company’s stock, valued at $7,803,614.56. The disclosure for this sale can be found here. 0.45% of the stock is currently owned by insiders.

Thermo Fisher Scientific stock traded up $4.93 during mid-day trading on Wednesday, hitting $294.43. 46,173 shares of the company’s stock were exchanged, compared to its average volume of 1,376,425. The company’s 50 day simple moving average is $280.88 and its 200-day simple moving average is $276.16. The company has a quick ratio of 1.07, a current ratio of 1.49 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $116.95 billion, a P/E ratio of 26.48, a PEG ratio of 1.91 and a beta of 1.12. Thermo Fisher Scientific Inc. has a fifty-two week low of $208.34 and a fifty-two week high of $305.45.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.01 by $0.03. The company had revenue of $6.32 billion during the quarter, compared to the consensus estimate of $6.31 billion. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.75 earnings per share. Research analysts expect that Thermo Fisher Scientific Inc. will post 12.24 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Tuesday, September 17th will be given a $0.19 dividend. The ex-dividend date is Monday, September 16th. This represents a $0.76 annualized dividend and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is presently 6.83%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: How is a management fee different from a performance fee?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.